Early Prediction of Subsequent Molecular Response to Nilotinib in Patients with Chronic Myeloid Leukemia-Reference-Cited by-同舟云学术

Early Prediction of Subsequent Molecular Response to Nilotinib in Patients with Chronic Myeloid Leukemia

Published:2020-10 Issue:10 Volume:22 Page:1217-1224
ISSN:1525-1578
Container-title:The Journal of Molecular Diagnostics
language:en
Short-container-title:The Journal of Molecular Diagnostics

Author:

Stuckey Ruth^ORCID,Casado Luis-Felipe,Colomer Dolors,Gómez-Casares María Teresa,Casas Laura,García-Gutierrez Valentín,Sastre José Luis,Ramírez-Payer Ángel,Vall-Llovera Ferrán,Goñi María Ángeles,Xicoy Blanca,Godoy Ana Cristina,Núñez Javier,Mora Itxaso,Vallansot Rolando,López-Lorenzo José Luis,Palomera Luis,Conesa Venancio,Noya María Soledad,Sánchez-Guijo Fermín,Peña Ascensión,Bautista Guiomar,Steegmann Juan Luis

Publisher

Elsevier BV

Subject

Molecular Medicine,Pathology and Forensic Medicine

Reference31 articles.

1. European LeukemiaNet recommendations for the management of chronic myeloid leukemia;Baccarani;Blood,2013

2. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results;Hughes;Blood,2006

3. First results from a collaborative initiative to develop an international scale for the measurement of BCR-ABL by RQ-PCR based on deriving laboratory-specific conversion factors [abstract];Branford;Blood,2006

4. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia;Hughes;N Engl J Med,2003

5. Laboratory recommendations for scoring deep molecular response following treatment for chronic myeloid leukemia;Cross;Leukemia,2015

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Measurable residual disease in chronic myeloid leukemia;Haematologica;2022-12-01

2. Initial Rate of BCR: : ABL1 Decline for Response Prediction in Chronic Myeloid Leukemia;Turkish Journal of Hematology;2022-08-24

3. Leukemia: Reduction Ratio and Halving Time of BCR: : ABL1 IS Transcript Levels;Turkish Journal of Hematology;2022-08-24

4. Discontinuation of Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia: a Review of the Biological Factors Associated with Treatment-Free Remission;Current Oncology Reports;2022-02-10